A Brief Insight about Role of YKL-40, EGF, suPAR as Biomarkers of Kidney Diseases

Abstract

Background:  In recent decades, the identification of new biomarkers of AKI has been the subject of interest by scientists worldwide. However, the predictive, diagnostic and prognostic ability of biomarkers in the context of iodinated contrast administration, has been less studied. In recent years, many additional potential biomarkers have been newly described for the early detection of tubular dysfunction/lesion associated with CM administration, to reliably measure CI‐AKI, and thus prevent patient outcomes.   Some of them are well characterized and categorized and could be divided into different groups in response to different physiological conditions: some involved in glomerular filtration e.g cyststin c, others related to the inflammatory response e.g. MCP-1,YKL-40,IL-18 and tubular cell injury e.g KIM-1,NGAL and LFABP or with a not well‐defined relationship with the disease and new emergent biomarkers under study e.g CTGF and suPAR.